RxDoctor Payments Data

Danny Phu, MD

Internal Medicine · Long Beach, CANPI 1518164094

Payments from drug & device makers

$1,984in general payments, 2019–2025

Across 86 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$223
  • Sumitomo Pharma America, Inc.$210
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
  • Lilly USA, LLC$155
  • Exact Sciences$148
  • Novartis$128
  • plus $939 from 16 others

What the payments were for

  • Food & beverage$1,93497%
  • Education$503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,984 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$155,657
Medicare patients
247
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$67,682
JardianceEmpagliflozin65$63,862
OzempicSemaglutide48$51,026
XareltoRivaroxaban37$35,301
FarxigaDapagliflozin Propanediol24$29,061
MounjaroTirzepatide28$25,833
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,267
Testosterone44$15,462
GemtesaVibegron23$15,377
EntrestoSacubitril/Valsartan17$15,098
MyrbetriqMirabegron16$14,632
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,188
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$12,305
Tresiba Flextouch U-100Insulin Degludec17$8,592
LinzessLinaclotide12$6,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$96$74,692130 claims
Boehringer IngelheimJardiance$72$63,86265 claims
AstraZenecaFarxiga, Breztri Aerosphere$54$43,24947 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$96$37,12452 claims
Johnson & JohnsonXarelto$102$35,30137 claims
Lilly USA, LLCMounjaro$155$25,83328 claims
Sumitomo Pharma America, Inc.Gemtesa$210$15,37723 claims
NovartisEntresto$128$15,09817 claims
AbbVieLinzess, Synthroid$223$10,65855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →